A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation.
Abu-Elmagd K, Costa G, Bond G, Soltys K, Martin L, Koritsky D, Cunha-Melo J, Sogawa H, Irish W, Tzakis A, Mazariegos G. A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation. Clinical Transplants 2012, 155-66. PMID: 23721018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlemtuzumabAnimalsAntibodies, Monoclonal, HumanizedAntilymphocyte SerumAntineoplastic AgentsFemaleGraft RejectionGraft SurvivalGraft vs Host DiseaseHumansImmunosuppressive AgentsIncidenceInfectionsIntestinesMaleMiddle AgedMorbidityPancreas TransplantationRabbitsStomachTransplantation, HomologousYoung AdultConceptsDose of rabbit antithymocyte globulinDe novo malignanciesRabbit antithymocyte globulinTacrolimus trough levelsLong-term immunosuppressionRe-transplantation rateLife-threatening infectionsLong-term survivalAntithymocyte globulinTacrolimus monotherapyAdrenal insufficiencyAllograft acceptanceRecipient pretreatmentTrough levelsImmunosuppressive strategiesSteroid-freeGraft lossSingle-doseAcute/chronic rejectionRe-transplantationGraft survivalMultivisceral transplantationSingle doseSerum sicknessAlemtuzumab pretreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply